Ingredient Guide
Valerian Root: Benefits, Dosage, and What the Research Says
One of the oldest herbal sleep aids in recorded medicine - here is an honest look at what the clinical evidence actually shows.
Written by Jessica Medson
Valerian root (Valeriana officinalis) is a perennial herb whose dried root has been used in traditional medicine for more than two thousand years as a calming remedy for sleep and nervous tension. A 2020 systematic review and meta-analysis of 60 studies involving 6,894 participants found that valerian may support subjective sleep quality with a favorable safety profile, though results across individual trials remain inconsistent. Current clinical evidence is most promising for subjective sleep quality and menopausal hot-flash symptoms; the evidence base for diagnosed anxiety disorders is limited and inconclusive.
What Is Valerian Root?
Valerian root is the dried root and rhizome of Valeriana officinalis, a flowering perennial plant native to Europe and Asia and now cultivated across North America. The name Valeriana is thought to derive from the Latin valere, meaning "to be in good health." Written accounts of its use as a calming remedy date to ancient Greece and Rome, and it remained a staple of European herbalism through the Middle Ages and into the eighteenth century, when it was widely used as a treatment for nervous unrest and poor sleep.
The root contains a complex mixture of bioactive compounds. The most studied is valerenic acid, a sesquiterpenic acid that serves as both the primary marker for standardization and a key driver of the plant's observed neurological effects.12 Other constituents include valepotriates (unstable iridoid compounds most abundant in the fresh root), isovaleric acid, lignans such as pinoresinol, flavonoids including linarin and hesperidin, and free gamma-aminobutyric acid (GABA) itself.12 The relative concentrations of these compounds vary significantly depending on the plant's geographic origin, harvest timing, and processing method, which is one reason clinical outcomes across studies are so inconsistent.
Commercial valerian products are available as encapsulated dried root powder, hydroalcoholic extracts standardized to 0.8% valerenic acid, teas, and liquid tinctures. Doses used in clinical trials have ranged widely from 225 mg to more than 1,200 mg per day. Notably, a 2020 meta-analysis found that whole root or rhizome preparations appeared to yield more consistent effects than isolated extracts, which may reflect synergistic activity among valerian's many constituents.1
Valerian is among the top-selling herbal supplements in the United States and European markets, classified as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) and not evaluated by the FDA for the treatment or prevention of any disease.
How Does Valerian Root Work?
Valerian is thought to act on the central nervous system through several overlapping pathways, the most studied of which involves the inhibitory neurotransmitter GABA.
GABA receptor modulation
Valerenic acid and related compounds have been shown in preclinical research to positively modulate GABA-A receptors, the same receptor family targeted by benzodiazepines and many prescription sleep medications, but through a distinct allosteric binding site rather than the classical benzodiazepine site.11 This distinction is pharmacologically meaningful: it suggests a potentially lower dependency risk, though human evidence on this point is limited. A 2021 narrative review of the available in vitro and animal data confirmed that valerenic acid's interaction with GABA-A receptors is the best-supported mechanistic explanation for valerian's calming properties, with contributions from isovaltrate, borneol, and several lignans also proposed.12
Effects on human cortical activity
Human neurophysiological research adds important context. A double-blind, crossover, placebo-controlled trial in 15 healthy volunteers found that a single 900 mg dose of valerian extract significantly reduced intracortical facilitation (ICF) as measured by transcranial magnetic stimulation, indicating that the extract modulates cortical excitatory circuits in living human brains.7 Effects peaked within one hour and returned to baseline by six hours post-dose. A separate four-week randomized controlled trial in 64 volunteers experiencing psychological stress found that valerian (100 mg three times daily) produced significantly greater increases in frontal brain alpha coherence compared to placebo, a pattern associated with calmer mental states, and these changes correlated with self-reported improvements in anxiolysis.6
Important caveats on mechanism
Most mechanistic work remains in preclinical models. Extrapolating animal GABA receptor data directly to expected human clinical outcomes is not straightforward, and the contributions of individual compounds versus the full herbal matrix are still being untangled. The human neuroimaging and neurophysiology studies cited above involve small samples and healthy volunteers, not clinical populations.
Valerian Root and Sleep Quality
Sleep support is by far the most-studied application of valerian root, with data from more than 60 clinical studies. The picture that emerges is one of modest, subjectively reported benefit in certain populations, inconsistent results across individual trials, and limited improvement on objective sleep measures.
What the research shows
The most comprehensive review to date, published in 2020, examined 60 studies totaling 6,894 participants and conducted meta-analyses on sleep quality (10 studies, n=1,065) and anxiety (8 studies, n=535). The authors found that valerian administration was associated with improvements in subjective sleep quality and reductions in anxiety, and reported no severe adverse events across participants aged 7 to 80 years.1 They observed that inconsistent results across studies likely reflected variability in extract quality and preparation, noting that whole root or rhizome products appeared to produce more reliable effects than processed or fractionated extracts.
An earlier systematic review and meta-analysis by Bent and colleagues analyzed 16 randomized, placebo-controlled trials (n=1,093 total) and found that the relative risk of improved sleep quality with valerian was 1.8 (95% CI: 1.2-2.9) on a dichotomous measure.2 However, the reviewers noted substantial methodologic limitations: average study quality was 3.4 out of 5, sample sizes were often small (8 of 16 trials enrolled fewer than 25 participants), and significant publication bias was detected, suggesting the true effect size is likely smaller than this pooled estimate.
A 2010 meta-analysis of 18 RCTs found a more modest but still statistically significant benefit: relative risk of improved subjective sleep quality was 1.37 (95% CI: 1.05-1.78) versus placebo.3 Objective sleep latency data were far less convincing, with pooled mean differences of only 0.70 minutes compared to placebo, a clinically negligible improvement.
Not all well-designed trials support a benefit. A phase III randomized, double-blind, placebo-controlled trial by the North Central Cancer Treatment Group enrolled 227 cancer patients with sleep disturbance and found no significant difference between valerian and placebo on the Pittsburgh Sleep Quality Index as the primary endpoint (area under the curve: 51.4 vs. 49.7 for placebo; p=0.6957).5 Exploratory secondary analyses did find significant improvement in fatigue scores with valerian, though this was not the pre-specified primary outcome.
In hemodialysis patients, a population with particularly high rates of sleep disturbance, a randomized, double-blind, crossover RCT found that valerian significantly reduced Pittsburgh Sleep Quality Index scores compared to placebo (mean change -7.6 vs. -3.2 points, p<0.001), alongside significant improvements in anxiety and depression scores.4
Bottom line: Clinical research suggests valerian may support subjective sleep quality in some populations when used nightly over four to eight weeks. The effect appears modest, results vary considerably across trial designs and populations, and objective sleep measures show minimal change. Individuals with clinically significant insomnia should discuss evidence-based treatment options, including cognitive behavioral therapy for insomnia (CBT-I), with a qualified healthcare provider.
Valerian Root and Anxiety
Valerian is frequently marketed for stress and generalized anxiety support. The biological rationale is plausible given its GABA-modulating properties, but the direct clinical evidence for diagnosed anxiety disorders is considerably weaker than the sleep literature.
What the research shows
A Cochrane systematic review on valerian for anxiety disorders identified only one eligible randomized controlled trial, enrolling 36 patients with generalized anxiety disorder over four weeks. No statistically significant differences were found between valerian and placebo on the Hamilton Anxiety Rating Scale (HAM-A). Diazepam, the active comparator, produced significantly greater symptom reduction on the State-Trait Anxiety Inventory (STAI) Trait subscale. The reviewers concluded that there is currently insufficient evidence to draw conclusions about valerian's efficacy or safety for anxiety disorders, and called for larger, well-designed trials.8
More recent research points toward neurophysiological effects that may be relevant to anxiety regulation, even if they have not yet translated to significant differences on standard clinical scales. A four-week RCT in 64 non-clinical volunteers experiencing psychological stress found that valerian extract (100 mg three times daily) produced significantly greater increases in frontal alpha brain coherence and decreases in theta coherence compared to placebo, and these brain connectivity changes correlated with self-reported anxiolytic effects - though the between-group difference on clinical anxiety rating scales was not statistically significant.6
In the hemodialysis patient RCT described in the sleep section, state anxiety scores were significantly reduced with valerian compared to placebo (mean change -14.6 vs. -7.3 points, p=0.003).4 This finding is noteworthy but reflects a specific clinical population with high baseline distress, and generalization to healthy adults is uncertain.
Bottom line: Preclinical mechanisms and preliminary human neuroimaging data suggest valerian may support a calmer mental state, but clinical trial evidence in people with diagnosed anxiety disorders is currently insufficient to support a strong conclusion. For anxiety management, consultation with a licensed healthcare provider is strongly recommended.
Valerian Root and Menopausal Symptoms
A less widely discussed application of valerian root - and one with a small but reasonably consistent clinical dataset - is the relief of hot flashes in menopausal and postmenopausal women, particularly those for whom conventional hormone therapy is not preferred or appropriate.
What the research shows
A double-blind, placebo-controlled RCT enrolled 68 menopausal women and administered 255 mg valerian capsules three times daily (765 mg/day total) or placebo for eight weeks. The valerian group showed statistically significant reductions in both hot flash severity (p<0.001) and frequency at four and eight weeks, while the placebo group showed no significant change. The between-group difference was significant at both time points (p<0.001).9
A triple-blind, randomized, placebo-controlled trial enrolled 60 postmenopausal women aged 45 to 55 and administered valerian 530 mg twice daily (1,060 mg/day total) or placebo for two months. Hot flash severity was significantly lower in the valerian group at one month (p=0.048) and two months (p=0.020), and hot flash frequency was significantly reduced at two months (p=0.033).10
Bottom line: Two small-to-moderate RCTs suggest that valerian may support reductions in hot flash severity and frequency in menopausal women over eight weeks of use. These findings are promising, but the samples are limited in size and longer-term data are lacking. Women should discuss all options for menopausal symptom management - including non-hormonal and hormonal approaches - with their healthcare provider.
Safety, Side Effects, and Drug Interactions
Valerian has a generally favorable safety record in clinical trials, but several important precautions apply.
Common side effects
The most frequently reported side effects across RCTs are mild and transient: drowsiness, dizziness, headache, vivid dreams, and gastrointestinal upset including stomach cramps or diarrhea. One larger trial (n=270) reported a notably higher rate of diarrhea with valerian versus placebo (18% vs. 8%).2 A 2020 meta-analysis of 60 studies found no severe adverse events in participants aged 7 to 80 at typical therapeutic doses.1
Drowsiness and impaired alertness
Because valerian may cause sedation, it should not be taken before driving, operating heavy machinery, or performing tasks requiring full mental alertness. The sedating effect may be stronger when first starting valerian and may diminish with regular use. Alcohol should be avoided when taking valerian.
Drug interactions
Valerian may enhance the sedating effects of central nervous system depressants, including prescription sleep medications (such as zolpidem or benzodiazepines), opioid pain medications, antihistamines, and alcohol. This additive sedation risk is the most clinically important interaction to be aware of. With respect to drug metabolism, a 14-day human pharmacokinetic study found that nightly doses of 1,000 mg valerian had minimal effects on CYP3A4 enzyme activity and no effect on CYP2D6 activity in healthy volunteers, suggesting that clinically significant metabolic interactions via these pathways are unlikely at typical doses.13 However, anyone taking prescription medications should consult a pharmacist or physician before beginning valerian.
Rare hepatotoxicity
A small number of published case reports have described elevated liver enzymes or jaundice temporally associated with valerian use, typically with symptom onset three to twelve weeks after initiation. Most cases involved valerian in combination with other botanical ingredients (such as skullcap or black cohosh), making causal attribution to valerian alone difficult. No cases of severe liver failure have been definitively linked to valerian alone. As a precaution, individuals with pre-existing liver conditions should exercise caution and consult a healthcare provider before use. Unexplained fatigue or yellowing of the skin while taking valerian should prompt medical evaluation.
Pregnancy and breastfeeding
Valerian has not been adequately studied in pregnant or breastfeeding women. Due to the presence of valerenic acid and valepotriates, whose effects on fetal development have not been established, valerian is not recommended during pregnancy or breastfeeding.
Withdrawal and discontinuation
Although evidence is limited to case reports, some users who abruptly stopped high-dose valerian after extended use have reported withdrawal-like symptoms including increased anxiety, agitation, and insomnia. Tapering doses gradually before discontinuing extended use is advisable.
Pediatric use
Some clinical studies have included children aged 7 and older without detecting major adverse events, but valerian is not generally recommended for children without specific guidance from a pediatrician or healthcare provider.
Valerian Root Dosage Guide
The following doses reflect those used in published clinical trials. No single dose has been established as optimal, and individual responses vary. These are not medical recommendations.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| Sleep quality support | 300-600 mg dried root extract (standardized to 0.8% valerenic acid) | 30-60 minutes before bedtime | Most RCTs used nightly dosing for 4-8 weeks. Acute single-dose effects may be less pronounced than effects after several weeks of consistent use. Whole root powder has also been used at 450-900 mg. |
| Stress and relaxation support | 100 mg extract three times daily (300 mg/day total) | Divided doses throughout the day, with meals | Based on Roh et al. 2019 four-week RCT in stressed volunteers. Evidence for anxiety benefit at any dose is limited; this dose is substantially lower than sleep-focused trials. |
| Menopausal hot flash support | 530-765 mg per day in divided doses | Twice or three times daily with meals | Derived from two RCTs (Mirabi 2013: 765 mg/day; Jenabi 2018: 1,060 mg/day) using 8-week treatment periods. Higher dose (1,060 mg/day) was used in the triple-blind trial. |
These statements have not been evaluated by the Food and Drug Administration. Valerian root is not intended to diagnose, treat, cure, or prevent any disease or condition. Consult a licensed healthcare provider before starting any herbal supplement, especially if you take prescription medications or have a medical condition.
Valerian Root: What the Evidence Shows at a Glance
This table summarizes the current state of clinical evidence across the main studied applications of valerian root.
| Outcome | Best available evidence | Key finding | Evidence strength |
|---|---|---|---|
| Subjective sleep quality | 3 meta-analyses covering 60+ RCTs (n up to 6,894) | RR 1.37-1.8 for improved sleep vs. placebo; most consistent with nightly use over 4-8 weeks | Tier A - multiple RCTs and meta-analyses; results mixed but directionally positive |
| Objective sleep latency | Pooled data from 18 RCTs (Fernandez-San-Martin 2010) | Mean difference of only 0.70 minutes vs. placebo - not clinically meaningful | Tier A - consistent across objective measures; no meaningful effect |
| Generalized anxiety disorder | Cochrane review: 1 eligible RCT, n=36 | No significant difference vs. placebo on HAM-A; insufficient evidence overall | Tier A - insufficient data; currently inconclusive |
| Brain relaxation markers | 2 small human RCTs (n=15 and n=64) | Reduced cortical facilitation; increased frontal alpha coherence correlated with relaxation | Tier A - mechanistic signal; small samples, healthy volunteers only |
| Menopausal hot flashes | 2 RCTs (n=60 and n=68, 8-week duration) | Significant reductions in hot flash frequency and severity vs. placebo in both trials | Tier A - promising; limited by small sample sizes and short follow-up |
| Drug metabolism safety | 1 human pharmacokinetic study, n=12, 14-day use | Minimal CYP3A4 effect; no CYP2D6 effect at 1,000 mg nightly | Tier A - reassuring for most medication combinations at typical doses |
Tier A = evidence derived from human randomized controlled trials or meta-analyses of RCTs. 'Mixed' or 'inconclusive' does not mean absence of effect - it reflects the current state of the evidence base, which includes methodologic limitations in many trials.
Frequently Asked Questions
What is valerian root good for?
Valerian root is most commonly used to support sleep quality and relaxation. Clinical research - including a 2020 meta-analysis of 60 studies (n=6,894) - suggests it may help improve subjective sleep quality with nightly use over 4-8 weeks. Smaller RCTs also suggest potential benefit for menopausal hot flashes. Evidence for diagnosed anxiety disorders is currently limited.
How much valerian root should I take for sleep?
Most clinical trials for sleep used 300-600 mg of standardized valerian extract (0.8% valerenic acid) taken 30-60 minutes before bedtime. Some trials used up to 900 mg of whole root. No universally optimal dose has been established. Starting at the lower end of the range and assessing tolerance is a reasonable approach.
How long does valerian root take to work?
Effects on sleep may take two to four weeks of nightly use to become noticeable. Unlike prescription sleep medications, valerian's effects appear to accumulate with consistent use rather than acting powerfully on the first night. Short-term single-dose studies show measurable changes in brain activity within one hour, but clinical sleep benefits are more consistently reported after extended use.
Does valerian root help with anxiety?
The evidence is currently insufficient to confirm valerian as an effective treatment for diagnosed anxiety disorders. A Cochrane review found only one eligible RCT (n=36) showing no significant difference versus placebo on anxiety scales. However, two small human trials found measurable changes in brain activity linked to relaxation. Valerian should not replace professional care for clinical anxiety.
Is valerian root safe to take every night?
A 2020 systematic review of 60 studies found no severe adverse events with valerian in participants aged 7-80. Most trials used 4-8 weeks of nightly dosing without safety signals. However, long-term use data beyond a few months are limited, and abrupt discontinuation after extended use may cause rebound anxiety in some individuals. Discuss prolonged use with a healthcare provider.
Can I take valerian root with melatonin?
No well-powered clinical trial has formally studied the valerian-melatonin combination. Both support relaxation and sleep onset through different mechanisms, and some combination products exist commercially. The main practical concern is additive drowsiness. Since neither has well-established severe drug interactions at typical doses, short-term combined use is sometimes considered by healthcare providers, but discuss with a clinician first.
What are the side effects of valerian root?
Common side effects are generally mild: drowsiness, headache, dizziness, vivid dreams, and gastrointestinal discomfort including diarrhea (reported in 18% vs. 8% for placebo in one large trial). Rare case reports describe liver enzyme elevations, mostly in people combining valerian with other botanicals. Drowsiness can impair driving and should be anticipated, particularly in new users.
Does valerian root interact with medications?
The most important interaction is with CNS depressants: prescription sleep aids, benzodiazepines, opioids, and antihistamines may all have additive sedating effects when combined with valerian. A 14-day human pharmacokinetic study found minimal impact on CYP3A4 and no effect on CYP2D6, suggesting low metabolic drug-drug interaction risk at typical doses. Always inform your pharmacist or prescriber before starting valerian.
Can valerian root help with menopause hot flashes?
Two randomized controlled trials in menopausal women (n=60 and n=68) found statistically significant reductions in hot flash frequency and severity after 8 weeks of valerian use compared to placebo. Doses ranged from 765 to 1,060 mg per day. These findings are promising, though sample sizes were small and longer-term follow-up data are not yet available.
Is valerian root addictive or habit-forming?
Valerian does not appear to act on the same binding sites as benzodiazepines, which are associated with dependency. No clinical trials have reported physical dependence. However, a small number of case reports describe withdrawal-like symptoms (anxiety, agitation) after abrupt cessation of extended high-dose use. Tapering rather than stopping suddenly is advisable after prolonged use.
Shop Valerian Root
HealthFare Valerian Root supplements
Scientific References
- 1.Shinjyo N, Waddell G, Green J Valerian Root in Treating Sleep Problems and Associated Disorders-A Systematic Review and Meta-Analysis. Journal of Evidence-Based Integrative Medicine. 2020. PubMed: 33086877Clinical (RCT / meta-analysis)
- 2.Bent S, Padula A, Moore D, Patterson M, Mehling W Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine. 2006. PubMed: 17145239Clinical (RCT / meta-analysis)
- 3.Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Medicine. 2010. PubMed: 20347389Clinical (RCT / meta-analysis)
- 4.Tammadon MR, Nobahar M, Hydarinia-Naieni Z, Ebrahimian A, Ghorbani R, Vafaei AA The Effects of Valerian on Sleep Quality, Depression, and State Anxiety in Hemodialysis Patients: A Randomized, Double-blind, Crossover Clinical Trial. Oman Medical Journal. 2021. PubMed: 33936782Clinical (RCT / meta-analysis)
- 5.Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, Rowland KM Jr, Zon RT, Lelindqwister NA, Nagargoje GG, Morgenthaler TI, Sloan JA, Loprinzi CL The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). Journal of Supportive Oncology. 2011. PubMed: 21399726Clinical (RCT / meta-analysis)
- 6.Roh D, Jung JH, Yoon KH, Lee CH, Kang LY, Lee SK, Shin K, Kim DH Valerian extract alters functional brain connectivity: A randomized double-blind placebo-controlled trial. Phytotherapy Research. 2019. PubMed: 30632220Clinical (RCT / meta-analysis)
- 7.Mineo L, Concerto C, Patel D, Mayorga T, Paula M, Chusid E, Aguglia E, Battaglia F Valeriana officinalis Root Extract Modulates Cortical Excitatory Circuits in Humans. Neuropsychobiology. 2017. PubMed: 29035887Clinical (RCT / meta-analysis)
- 8.Miyasaka LS, Atallah AN, Soares BGO Valerian for anxiety disorders. Cochrane Database of Systematic Reviews. 2006. PubMed: 17054208Clinical (RCT / meta-analysis)
- 9.Mirabi P, Mojab F The effects of valerian root on hot flashes in menopausal women. Iranian Journal of Pharmaceutical Research. 2013. PubMed: 24250592Clinical (RCT / meta-analysis)
- 10.Jenabi E, Shobeiri F, Hazavehei SMM, Roshanaei G The effect of Valerian on the severity and frequency of hot flashes: A triple-blind randomized clinical trial. Women and Health. 2018. PubMed: 28278010Clinical (RCT / meta-analysis)
- 11.Becker A, Felgentreff F, Schroeder H, Meier B, Brattstrom A The anxiolytic effects of a Valerian extract is based on valerenic acid. BMC Complementary and Alternative Medicine. 2014. PubMed: 25066015Preclinical (animal / cell)
- 12.Orhan IE A Review Focused on Molecular Mechanisms of Anxiolytic Effect of Valeriana officinalis L. in Connection with Its Phytochemistry through in vitro/in vivo Studies. Current Pharmaceutical Design. 2021. PubMed: 33463459Preclinical (animal / cell)
- 13.Donovan JL, DeVane CL, Chavin KD, Wang JS, Gibson BB, Gefroh HA, Markowitz JS Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metabolism and Disposition. 2004. PubMed: 15328251Clinical (RCT / meta-analysis)